With Siemens close on its heels, Philips became the first company to get the green light to market its hybrid whole body PET/MR imaging system. Royal Philips Electronics announced this week that it received a CE marking, allowing the company to begin selling in Europe.
With Siemens close on its heels, Philips became the first company to get the green light to market its hybrid whole body PET/MR imaging system. Royal Philips Electronics announced this week that it received a CE marking, allowing the company to begin selling in Europe.
Philips’ system, called the Ingenuity TF PET/MR, can be used to screen for high-risk heart disease, with the goal of imaging diseased cells before they become coronary plaques. It can also be used for oncology, detecting tumor formation or recurrence, and monitoring drug delivery to tumors on a cellular level.
The Ingenuity “is able to effectively image the prostate for the first time and detect deadly cancers in organs such as the pancreas at a significantly earlier stage," said Dominic Smith, vice president of marketing, Computed Tomography and Nuclear Medicine, for Philips Healthcare.
The PET scanner’s molecular imaging capability is combined with the MRI’s soft tissue contrast, to spotlight disease cells in soft tissue. “The Ingenuity TF PET/MR provides researchers and clinicians an unprecedented opportunity to make earlier diagnoses and personalize treatments for oncology and cardiology," said Smith.
Siemens is also in the late stages of developing a much-anticipated hybrid machine with a different design but the same modalities. GE already has a commercially available technology that fuses PET and MR images using their specialized software.
Philips’ Ingenuity system places MR and PET scanners almost 10 feet apart, with a table rotating the patient for scanning by each. The PET and MR machines can work independently as well. The PET/MR system is the first new modality for Philips in 10 years, and it produces up to 70 percent less ionizing radiation than the PET/CT, according to the company.
While not yet available commercially in the U.S., the company is gathering data for the FDA application from the Ingenuity’s installation at Mount Sinai School of Medicine in New York, as well as Helmholtz-Zentrum Dresden-Rossendorf (HZDR) in Dresden, Germany, and University Hospital in Geneva, Switzerland.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
August 1st 2025An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 1st 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
August 1st 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
August 1st 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.